



**Neuren (NEU) - ASX Announcement**

**30 July 2020**

## **Appointment of CFO & Company Secretary**

**Melbourne, Australia, 30 July 2020:** Neuren Pharmaceuticals (ASX: NEU) today announced the appointment of Lauren Frazer as Chief Financial Officer and Company Secretary, effective 1 August 2020. Lauren joined Neuren in March 2020 from Boundary Bend, one of Australia’s leading agribusinesses. Lauren is a Chartered Accountant, formerly with Pitcher Partners.

Neuren CEO Jon Pilcher commented: “Lauren has already made a strong contribution during her short time at Neuren and I look forward to working with her as we seek to realise the value of the great opportunities that lie ahead for trofinetide and NNZ-2591”.

### **About Neuren**

Neuren is developing new therapies for neurodevelopmental disorders with high unmet need, utilizing synthetic analogs of neurotrophic peptides that occur naturally in the brain. Trofinetide is currently in a Phase 3 clinical trial for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs have each received Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Neuren has granted an exclusive license to ACADIA Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, whilst retaining all rights outside North America. Neuren is advancing the development of NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes, each of which has received Orphan Drug designation in the United States.

### **Contact:**

Jon Pilcher, CEO  
jpilcher@neurenpharma.com; +61 438 422 271

### **ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the board of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

### *Forward-looking Statements*

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*